98010-38-9Relevant academic research and scientific papers
OGA INHIBITOR COMPOUNDS
-
, (2021/06/26)
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.
Wnt signal pathway inhibitor and use thereof
-
Paragraph 0047; 0115; 0116; 0119; 0120, (2017/08/10)
The invention relates to heterocyclic compounds with Wnt signal channel inhibition activity, particularly including compounds, pharmaceutically acceptable salts, various isotopes, various isomers or various crystal structures thereof having a structure represented by a general formula I (shown in the specification). By the compounds and a composition of the compounds, a Wnt signal channel can be effectively inhibited and diseases related to the Wnt signal channel can be treated or prevented.
UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
-
Page/Page column 115, (2010/11/23)
The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): [Chemical formula I] wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is -C(O)-, -S(O)-, or -S(O)2-; W is -N(R2)-, -O-, or a bond (wherein R2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is -C(O)-, -S(O)-, or -S(O)2-; Z is a bond, a chain hydrocarbon group which may be substituted, or -N=; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2]------￣?,?------? are each independently a single bond or a double bond; provided that R1 may be bonded to R2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.
Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents
-
, (2008/06/13)
A series of novel 4-substituted piperazinyl-pyridine and 4-substituted piperazinyl-imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the 4-substituent is a lower phenylalkyl group or a derivative thereof further substituted on the phenyl moiety by a sulphamoyl or sulphonylamino group or by a nitro, amino or acetamido group. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrythmias. The most preferred member compound of the series is N-{4-[1-hydroxy-2-(4-[4-pyridinyl]-1-piperazinyl)ethyl]phenyl} methanesulphonamide. Methods for preparing all these compounds from known starting materials are provided.
Phenyl piperazine anti-arrhythmia agents
-
, (2008/06/13)
A series of pyridyl or imidazolyl substituted phenyl piperazines having utility as anti-arrhythmic agents is disclosed.
